Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 8/20 | 0.71 |
| ▸ | FNTB | P49356 | 6/20 | 0.71 |
| ▸ | PGGT1B | P53609 | 3/20 | 0.69 |
| ▸ | TRPV1 | Q8NER1 | 6/20 | 0.66 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1723041 | 1.00 | FNTA (0.71) | FNTAFNTBPGGT1BTRPV1TRPA1 | |
| SCHEMBL16770097 | 0.95 | FNTA (0.66) | FNTAFNTBPGGT1BTRPV1TRPA1 | |
| SCHEMBL15161516 | 0.93 | FNTA (0.64) | FNTAFNTBPGGT1BTRPV1TRPA1 | |
| SCHEMBL8940673 | 0.92 | FNTA (0.67) | FNTAFNTBPGGT1BTRPV1TRPA1 | |
| SCHEMBL8940669 | 0.92 | FNTA (0.67) | FNTAFNTBPGGT1BTRPV1TRPA1 | |
| SCHEMBL12511782 | 0.91 | FNTA (0.66) | FNTAFNTBPGGT1BTRPV1TRPA1 | |
| SCHEMBL13146186 | 0.91 | FNTA (0.66) | FNTAFNTBPGGT1BTRPV1TRPA1 | |
| SCHEMBL1724882 | 0.90 | FNTA (0.61) | FNTAFNTBPGGT1BTRPV1TRPA1 | |
| SCHEMBL1724883 | 0.90 | FNTA (0.61) | FNTAFNTBPGGT1BTRPV1TRPA1 | |
| SCHEMBL19734473 | 0.90 | FNTA (0.68) | FNTAFNTBPGGT1BTRPV1TRPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2399899-B1 | Geranyl compounds | OHGEN RES LAB LTD (JP) | 2013-08-07 | — | — | EP | disclosed |
| EP-2404894-A1 | Mevalonic Acid Derivatives | Ohgen Research Laboratories Ltd. (JP) | 2012-01-11 | — | — | EP | disclosed |
| EP-2399899-A1 | Geranyl compounds | Ohgen Research Laboratories Ltd. (JP) | 2011-12-28 | — | — | EP | disclosed |
| EP-2399900-A1 | Geranyl compounds | Ohgen Research Laboratories Ltd. (JP) | 2011-12-28 | — | — | EP | disclosed |
| US-7579376-B2 | N-geranoyltyrosine and N-geranoylcycteine as excellant antitumor and anticarcinogenic agents | OHGEN RESEARCH LABORATORIES, LTD. (JP) | 2009-08-25 | — | — | US | disclosed |
| US-7579376-B2 | N-geranoyltyrosine and N-geranoylcycteine as excellant antitumor and anticarcinogenic agents | OHGEN RESEARCH LABORATORIES, LTD. (JP) | 2009-08-25 | — | — | US | disclosed |
| US-7553820-B2 | Mevalonic acid derivatives | OHGEN RESEARCH LABORATORIES, LTD. (JP) | 2009-06-30 | — | — | US | disclosed |
| US-7553820-B2 | Mevalonic acid derivatives | OHGEN RESEARCH LABORATORIES, LTD. (JP) | 2009-06-30 | — | — | US | disclosed |
| US-7507765-B2 | Geranyl compounds | OHGEN RESEARCH LABORATORIES, LTD. (JP) | 2009-03-24 | — | — | US | disclosed |
| US-7507765-B2 | Geranyl compounds | OHGEN RESEARCH LABORATORIES, LTD. (JP) | 2009-03-24 | — | — | US | disclosed |
| US-20080119556-A1 | Geranly compounds | AKIYAMA KIYOSHI | 2008-05-22 | — | — | US | disclosed |
| US-20080113939-A1 | Geranyl compounds | AKIYAMA KIYOSHI | 2008-05-15 | — | — | US | disclosed |
| US-7125852-B2 | Geranyl compounds | OHGEN RESEARCH LABORATORIES, LTD. (JP) | 2006-10-24 | — | — | US | disclosed |
| EP-1471052-A1 | GERANYL COMPOUNDS | Ohgen Research Laboratories Ltd. (JP) | 2004-10-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080113939-A1 | Geranyl compounds | GGPS1, FNTA, CCNE2 | FNTA 2/4885FNTB 64/4885PGGT1B 30/4885 |
| US-20080119556-A1 | Geranly compounds | GMNN, TP53, MCL1 | FNTA 406/4885FNTB 1727/4885PGGT1B 470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.